Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Waters (WAT) stock in plain English

Free brief · no signupStart here
WATPublished Nov 16, 2026
Waters Corp
Healthcare · Diagnostics & Research
Manufactures liquid chromatography systems, mass spectrometers, and thermal analysis instruments for chemical testing.
Assets:
Taunton chemistry plantSynthesizes chromatographic silica and specialized consumables at a primary facility in Massachusetts.
Wyatt TechnologyProduces light-scattering instruments and nanoparticle characterization tools based in California.
TA InstrumentsOperates a dedicated thermal analysis and rheology hardware manufacturing base in New Castle, Delaware.
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

56
OPS ScoreOperating finances
Latest quote
-2.06%$456.48
$44.87B
196.3×
$5.61B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 16, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was WAT. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Waters (WAT) do?

Waters Corp (WAT) is a U.S.-listed company in Healthcare (Diagnostics & Research). What it does: Manufactures liquid chromatography systems, mass spectrometers, and thermal analysis instruments for chemical testing. It supplies analytical instruments and specialized consumables used by pharmaceutical laboratories to verify chemical. It is worth $44.87B on the market and sold $5.61B over the last year.

Market cap
$44.87B
P/E ratio
196.3×
Annual sales
$5.61B
Sector
Healthcare
Industry
Diagnostics & Research
Brief updated
Nov 16, 2026

Brands and businesses behind WAT

  • TA Instruments: Sells thermal analysis, microcalorimetry, and rheology instruments to materials science and biopharma labs.
  • Wyatt Technology: Manufactures light-scattering instruments and biophysical characterization tools sold directly to researchers.
  • ACQUITY: Sells ultra-performance liquid chromatography systems and consumable separation columns to pharmaceutical laboratories.
  • Empower: Licenses enterprise chromatography data software that collects and manages laboratory testing records for compliance.

WAT’s flags, in plain English

Each flag is a number from Waters’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 16, 2026.

Stupid Cash

Can pay this year's bills 1.9 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 36% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Priced for Perfection

Priced at 196.3 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.

Questions about WAT

How big is Waters?

Waters’ market cap is $44.87B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $5.61B: what customers paid the company over the last year, before any costs.

What is WAT’s P/E ratio?

WAT’s P/E ratio is 196.3×. Investors pay about 196.3 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with WAT?

A substantial portion of instrument sales relies on pharmaceutical capital budgets, which face pressure when drugmakers curtail lab spending. That is one risk on Waters’ card. Its first risk flag is Priced for Perfection, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Waters’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. WAT’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card